Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

NCT00379613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Anesthesia, General

Interventions

DRUG: sugammadex
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC